Status:
COMPLETED
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse
Lead Sponsor:
Zhejiang University
Conditions:
Measurable Residual Disease
Eligibility:
All Genders
12-70 years
Brief Summary
A study on the Effectiveness of digital droplet PCR in monitoring measurable residual disease during the early period after allogeneic hematopoietic stem cell transplantation to predict patients at hi...
Detailed Description
This is a retrospective and multicenter clinical study.This study is indicated for patients with hematological malignancies who underwent allo-HSCT. It aims to evaluate the effectiveness of digital dr...
Eligibility Criteria
Inclusion
- The presence of at least one haematological tumour-associated mutation or fusion gene detected at diagnosis by NGS or real-time qPCR provided for posttransplant MRD monitoring;
- Successful stem cell engraftment
- Received at least one bone marrow MRD detection by ddPCR in +30 days to +120 days after HSCT;
- Age 12-70
Exclusion
- Patients who relapsed or died before the first ddPCR monitoring;
- Patients with only germline mutations.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT06000306
Start Date
January 1 2018
End Date
July 31 2023
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, China